Skip to content

US · OM · MEDICAL - DEVICES

Outset Medical, Inc. (OM) intrinsic value and stock valuation

$2.81as of 2026-11-21 · Mkt cap 90.83M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Outset Medical, Inc. DCF and intrinsic value

InvestorsCraft values OM with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OM’s statements →

Outset Medical, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices San Jose, CA 95134 outsetmedical.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$119.5M+19.1% 5y CAGRd
20182025
Net income
-$-81.65M
20182025
Free cash flow
-$-47.12M
20182025
Total equity
$127M-17.3% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$119.5M$113.7M$130.4M$115.4M$102.6M
Operating income-$-66.71M-$-113.38M-$-169.77M-$-161.02M-$-130.52M
Net income-$-81.65M-$-127.98M-$-172.8M-$-162.96M-$-131.94M
EPSd-$-5.37M-$-36.99M-$-52.21M-$-50.77M-$-43.4M
Operating cash flow-$-46.33M-$-116.3M-$-131.37M-$-145.73M-$-130.26M
Capital expenditure-$-800K-$-910K-$-3.44M-$-8.32M-$-3.11M
Free cash flow-$-47.12M-$-117.22M-$-134.81M-$-154.05M-$-133.37M
Total assets$264.5M$275.8M$313.8M$400.1M$463.5M
Total debt$101.3M$201.9M$136.2M$103.2M$37.8M
Net debt$66.2M$77.8M$67.7M$30M-$-144.54M
Total equity$127M$26.8M$122.9M$246M$374.1M
Cash and short-term investments$169M$158.7M$203.3M$287.5M$339.5M
Income statement
20252024202320222021
Revenue$119.5M$113.7M$130.4M$115.4M$102.6M
Cost of revenue$72.7M$75.1M$101.4M$97.5M$95M
Gross profit$46.8M$38.6M$29M$17.8M$7.61M
Research and development expenses$21.2M$38.4M$57.3M$48.9M$36.7M
Selling, general and administrative expenses$92.2M$113.5M$141.5M$130M$101.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$113.5M$151.9M$198.8M$178.9M$138.1M
Cost and expenses$186.2M$227.1M$300.2M$276.4M$233.1M
Interest income$7.41M$9.76M$10.2M$3.29M$500K
Interest expense$14M$23.9M$12.7M$3.57M$1.72M
Depreciation and amortization$4.34M$5.73M$5.81M$6.28M$5.16M
Ebitda-$-62.37M-$-97.89M-$-153.79M-$-152.81M-$-124.86M
Operating income-$-66.71M-$-113.38M-$-169.77M-$-161.02M-$-130.52M
Total other income/expenses, net-$-14.22M-$-14.11M-$-2.5M-$-1.64M-$-1.22M
Income before tax-$-80.94M-$-127.48M-$-172.27M-$-162.66M-$-131.74M
Income tax expense$720K$490K$520K$290K$200K
Net income-$-81.65M-$-127.98M-$-172.8M-$-162.96M-$-131.94M
Weighted average shares outstanding$15.2M$3.46M$3.31M$3.21M$3.04M
Weighted average diluted shares outstanding$15.2M$3.46M$3.31M$3.21M$3.04M
Balance sheet
20252024202320222021
Cash and short-term investments$169M$158.7M$203.3M$287.5M$339.5M
Net receivables$28.3M$35.6M$33M$28.1M$25.6M
Inventory$47.6M$59.4M$49.2M$51.5M$39.2M
Total current assets$250.9M$258.2M$291.2M$373.6M$409.8M
Property, plant and equipment, net$9.47M$12.1M$18.7M$22M$20.2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$3.83M$3.33M$3.33M$3.31M$33.3M
Total non-current assets$13.6M$17.6M$22.6M$26.5M$53.7M
Total assets$264.5M$275.8M$313.8M$400.1M$463.5M
Accounts payable$550K$3.86M$5.83M$600K$1.76M
Short-term debt$1.74M$3.6M$1.59M$1.32M$1.15M
Deferred revenue$13.8M$12.8M$11.7M$8.66M$6.34M
Total current liabilities$37.6M$45.4M$55.3M$52M$51.7M
Long-term debt$99.5M$200.1M$134.6M$101.9M$36.7M
Deferred revenue, non-current$410K$840K$100K$150K$310K
Total non-current liabilities$99.9M$203.6M$135.6M$102.2M$37.7M
Capital lease obligations$5.01M$4.48M$6.08M$6.89M$8.04M
Total liabilities$137.5M$249M$190.9M$154.1M$89.4M
Common stock$20K$50K$50K$50K$50K
Retained earnings-$-1.17B-$-1.09B-$-961.75M-$-788.95M-$-625.99M
Accumulated other comprehensive income (loss)$170K$40K$70K-$-560K-$-180K
Total equity$127M$26.8M$122.9M$246M$374.1M
Total investments$137.8M$38M$134.8M$217.6M$190.5M
Total debt$101.3M$201.9M$136.2M$103.2M$37.8M
Net debt$66.2M$77.8M$67.7M$30M-$-144.54M
Cash flow statement
20252024202320222021
Net income-$-81.65M-$-127.98M-$-172.8M-$-162.96M-$-131.94M
Depreciation and amortization$4.34M$5.73M$5.81M$5.17M$5.16M
Stock-based compensation$15.6M$29.4M$38.6M$27.2M$17.5M
Change in working capital$2.2M-$-25.69M-$-770K-$-21.14M-$-25.6M
Accounts receivable$3.77M-$-5.01M-$-5.09M-$-2.51M-$-19.14M
Inventory$11.8M-$-10.86M$1.65M-$-14.73M-$-22.04M
Accounts payable-$-3.29M-$-1.95M$5.31M-$-1.28M-$-3.07M
Net cash provided by operating activities-$-46.33M-$-116.3M-$-131.37M-$-145.73M-$-130.26M
Investments in property, plant and equipment-$-800K-$-910K-$-3.44M-$-8.32M-$-3.11M
Acquisitions, net$0.00$0.00$0.00$58M$139.4M
Net cash used for investing activities-$-97.68M$103.9M$83M-$-66.3M-$-142.51M
Common stock issued$162.2M$2.28M$10.4M$8.04M$149.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$55.5M$67.9M$43.7M$72.9M$160.2M
Net change in cash-$-88.51M$55.5M-$-4.7M-$-139.13M-$-112.62M
Cash at end of period$38.8M$127.3M$71.8M$76.5M$215.7M
Operating cash flow-$-46.33M-$-116.3M-$-131.37M-$-145.73M-$-130.26M
Capital expenditure-$-800K-$-910K-$-3.44M-$-8.32M-$-3.11M
Free cash flow-$-47.12M-$-117.22M-$-134.81M-$-154.05M-$-133.37M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Outset Medical, Inc.

        Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts integrated water purification, on-demand production of dialysate, and advanced software complete with connectivity features. Founded in 2003, the company initially operated under the name Home Dialysis Plus, Ltd. before rebranding to Outset Medical, Inc. in January 2015. Its corporate headquarters are located in San Jose, California.

        CEO
        Leslie L. Trigg
        Employees
        310
        Beta
        1.94

        Explore

        Frequently asked questions

        What is the intrinsic value of Outset Medical, Inc. (OM)?

        Outset Medical, Inc. (OM) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is OM undervalued?

        OM trades at a price of $2.81 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.